Across TCGA pan-cancer cohorts, CHRM5 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CHRM5 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CHRM5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHRM5 expression acts as an unfavorable survival marker.

LUSC are the cancer types where CHRM5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.064	0.791	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: CHRM5 tumor-vs-normal RNA expression · all CHRM5 data types